(MDT) Medtronic - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 110.491m USD | Total Return: 1.7% in 12m

Stock Pacemakers, Defibrillators, Valves, Stents, Pumps
Total Rating 58
Safety 92
Buy Signal 0.57
Medical Devices -6.2
Health Care Equipment -3.7
Market Cap: 110,491m
Avg Trading Vol: 729M USD
ATR: 2.16%
Peers RS (IBD): 55.4
Risk 5d forecast
Volatility19.8%
Rel. Tail Risk-4.81%
Reward TTM
Sharpe Ratio-0.13
Alpha-7.32
Character TTM
Beta0.361
Beta Downside0.187
Drawdowns 3y
Max DD22.77%
CAGR/Max DD0.28
EPS (Earnings per Share) EPS (Earnings per Share) of MDT over the last years for every Quarter: "2021-04": 1.5, "2021-07": 1.41, "2021-10": 1.32, "2022-01": 1.37, "2022-04": 1.52, "2022-07": 1.13, "2022-10": 1.3, "2023-01": 1.3, "2023-04": 1.57, "2023-07": 1.2, "2023-10": 1.25, "2024-01": 1.3, "2024-04": 1.46, "2024-07": 1.23, "2024-10": 1.26, "2025-01": 1.39, "2025-04": 1.62, "2025-07": 1.26, "2025-10": 1.36, "2026-01": 1.36,
EPS CAGR: -2.92%
EPS Trend: 20.7%
Last SUE: 2.12
Qual. Beats: 5
Revenue Revenue of MDT over the last years for every Quarter: 2021-04: 8188, 2021-07: 7987, 2021-10: 7847, 2022-01: 7763, 2022-04: 8089, 2022-07: 7371, 2022-10: 7585, 2023-01: 7727, 2023-04: 8544, 2023-07: 7702, 2023-10: 7984, 2024-01: 8089, 2024-04: 8589, 2024-07: 7915, 2024-10: 8403, 2025-01: 8292, 2025-04: 8927, 2025-07: 8578, 2025-10: 8961, 2026-01: 9018,
Rev. CAGR: 2.94%
Rev. Trend: 79.8%
Last SUE: 1.63
Qual. Beats: 3
Description: MDT Medtronic

Medtronic plc (NYSE: MDT) is a global leader in device-based medical therapies, operating across four main portfolios: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. The company designs and sells a broad array of products-from implantable cardiac devices and aortic valves to spinal cord stimulators, robotic-assisted surgical tools, and continuous glucose monitoring systems-serving hospitals, physicians, and patients worldwide.

In its most recent fiscal year (2023), Medtronic generated $31.7 billion in revenue, with an operating margin of 27% and earnings per share of $8.70. R&D spending reached $2.2 billion, reflecting a continued focus on next-generation minimally invasive technologies. The firm’s growth is bolstered by macro-drivers such as an aging global population, rising prevalence of chronic diseases, and sustained U.S. healthcare spending growth of roughly 5% YoY.

For a deeper dive, you might explore ValueRay’s analyst tools.

Headlines to Watch Out For
  • New product
Piotroski VR‑10 (Strict) 6.5
Net Income: 4.61b TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.16 > 1.0
NWC/Revenue: 41.08% < 20% (prev 32.15%; Δ 8.93% < -1%)
CFO/TA 0.08 > 3% & CFO 7.29b > Net Income 4.61b
Net Debt (26.92b) to EBITDA (9.36b): 2.88 < 3
Current Ratio: 2.54 > 1.5 & < 3
Outstanding Shares: last quarter (1.29b) vs 12m ago 0.16% < -2%
Gross Margin: 61.95% > 18% (prev 0.65%; Δ 6.13k% > 0.5%)
Asset Turnover: 39.11% > 50% (prev 36.90%; Δ 2.21% > 0%)
Interest Coverage Ratio: 8.81 > 6 (EBITDA TTM 9.36b / Interest Expense TTM 712.0m)
Altman Z'' 3.35
A: 0.16 (Total Current Assets 24.07b - Total Current Liabilities 9.49b) / Total Assets 91.48b
B: 0.35 (Retained Earnings 32.30b / Total Assets 91.48b)
C: 0.07 (EBIT TTM 6.27b / Avg Total Assets 90.73b)
D: 0.66 (Book Value of Equity 27.79b / Total Liabilities 42.29b)
Altman-Z'' Score: 3.35 = A
Beneish M -3.78
DSRI: 0.01 (Receivables 87.0m/6.12b, Revenue 35.48b/33.20b)
GMI: 1.05 (GM 61.95% / 65.27%)
AQI: 0.98 (AQ_t 0.66 / AQ_t-1 0.68)
SGI: 1.07 (Revenue 35.48b / 33.20b)
TATA: -0.03 (NI 4.61b - CFO 7.29b) / TA 91.48b)
Beneish M-Score: -3.78 (Cap -4..+1) = AAA
What is the price of MDT shares? As of April 04, 2026, the stock is trading at USD 86.65 with a total of 7,341,269 shares traded.
Over the past week, the price has changed by -0.59%, over one month by -9.69%, over three months by -10.29% and over the past year by +1.70%.
Is MDT a buy, sell or hold? Medtronic has received a consensus analysts rating of 3.81. Therefore, it is recommended to buy MDT.
  • StrongBuy: 12
  • Buy: 5
  • Hold: 13
  • Sell: 1
  • StrongSell: 1
What are the forecasts/targets for the MDT price?
Wallstreet Target Price 110.6 27.6%
Analysts Target Price 110.6 27.6%
MDT Fundamental Data Overview as of 03 April 2026
P/E Trailing = 24.0391
P/E Forward = 14.1044
P/S = 3.1138
P/B = 2.2556
P/EG = 1.5009
Revenue TTM = 35.48b USD
EBIT TTM = 6.27b USD
EBITDA TTM = 9.36b USD
Long Term Debt = 27.82b USD (from longTermDebt, last quarter)
Short Term Debt = 191.0m USD (from shortTermDebt, last quarter)
Debt = 28.07b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 26.92b USD (from netDebt column, last quarter)
Enterprise Value = 130.18b USD (110.49b + Debt 28.07b - CCE 8.38b)
Interest Coverage Ratio = 8.81 (Ebit TTM 6.27b / Interest Expense TTM 712.0m)
EV/FCF = 24.06x (Enterprise Value 130.18b / FCF TTM 5.41b)
FCF Yield = 4.16% (FCF TTM 5.41b / Enterprise Value 130.18b)
FCF Margin = 15.25% (FCF TTM 5.41b / Revenue TTM 35.48b)
Net Margin = 13.00% (Net Income TTM 4.61b / Revenue TTM 35.48b)
Gross Margin = 61.95% ((Revenue TTM 35.48b - Cost of Revenue TTM 13.50b) / Revenue TTM)
Gross Margin QoQ = 64.89% (prev 60.32%)
Tobins Q-Ratio = 1.42 (Enterprise Value 130.18b / Total Assets 91.48b)
Interest Expense / Debt = 0.64% (Interest Expense 181.0m / Debt 28.07b)
Taxrate = 18.09% (254.0m / 1.40b)
NOPAT = 5.14b (EBIT 6.27b * (1 - 18.09%))
Current Ratio = 2.54 (Total Current Assets 24.07b / Total Current Liabilities 9.49b)
Debt / Equity = 0.57 (Debt 28.07b / totalStockholderEquity, last quarter 48.98b)
Debt / EBITDA = 2.88 (Net Debt 26.92b / EBITDA 9.36b)
Debt / FCF = 4.98 (Net Debt 26.92b / FCF TTM 5.41b)
Total Stockholder Equity = 48.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.09% (Net Income 4.61b / Total Assets 91.48b)
RoE = 9.54% (Net Income TTM 4.61b / Total Stockholder Equity 48.39b)
RoCE = 8.23% (EBIT 6.27b / Capital Employed (Equity 48.39b + L.T.Debt 27.82b))
RoIC = 6.68% (NOPAT 5.14b / Invested Capital 76.91b)
WACC = 5.89% (E(110.49b)/V(138.56b) * Re(7.25%) + D(28.07b)/V(138.56b) * Rd(0.64%) * (1-Tc(0.18)))
Discount Rate = 7.25% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 0.05%
[DCF] Terminal Value 86.50% ; FCFF base≈5.43b ; Y1≈5.52b ; Y5≈6.06b
[DCF] Fair Price = 118.9 (EV 179.59b - Net Debt 26.92b = Equity 152.67b / Shares 1.28b; r=6.0% [WACC]; 5y FCF grow 1.39% → 3.0% )
EPS Correlation: 20.72 | EPS CAGR: -2.92% | SUE: 2.12 | # QB: 5
Revenue Correlation: 79.82 | Revenue CAGR: 2.94% | SUE: 1.63 | # QB: 3
EPS next Quarter (2026-07-31): EPS=1.37 | Chg7d=-0.001 | Chg30d=-0.004 | Revisions Net=-3 | Analysts=20
EPS next Year (2027-04-30): EPS=6.06 | Chg7d=-0.027 | Chg30d=-0.032 | Revisions Net=-1 | Growth EPS=+9.8% | Growth Revenue=+6.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.8% (Discount Rate 7.9% - Earnings Yield 4.2%)
[Growth] Growth Spread = +5.7% (Analyst 9.5% - Implied 3.8%)
External Resources
Dataroma Stockcircle